Pre-vaccination seroprevalence of SARS-CoV-2 antibodies in the Volta Region, Ghana
- PMID: 38328557
- PMCID: PMC10847139
- DOI: 10.1016/j.ijregi.2024.01.007
Pre-vaccination seroprevalence of SARS-CoV-2 antibodies in the Volta Region, Ghana
Abstract
Objectives: Before administration of the first dose of the AstraZeneca 2019 SARS-CoV-2 vaccine to selected prioritized groups in the Volta regional capital of Ghana, we determined the pre-vaccination status of prospective recipients and established the baseline exposure status 1 year after the first case was reported.
Methods: After informed consent, blood samples were collected for the detection of SARS-CoV-2 immunoglobulin (Ig) M/IgG antibodies using rapid diagnostic test kits. A total of 409 individuals (mean age 27 years) consented and participated in the study, comprising 70% students and others were health staff and educators who presented themselves for vaccination.
Results: The overall exposure rate of SARS-CoV-2 was 12.7% (95% confidence interval [CI] 9.6-16.3). The prevalence of SARS-CoV-2 IgM and IgG were 4.2% (95% CI 2.4-6.6) and 5.6% (95% CI 3.6-8.3), respectively. IgM and IgG were detected in 2.9% (95% CI 1.5-5.1) of the respondents. The exposure rates were higher in participants over 40 years old (15.5%). Participants without a history of COVID-19-like symptoms had an exposure rate of 13.0% and those without any chronic diseases was 13.2%.
Conclusion: Pre-vaccination exposure was relatively low and underscored the need for vaccination i to increase protection in communities and disease outcomes.
Keywords: COVID-19; Exposure; Pandemic; SARS-CoV-2; Vaccination.
© 2024 The Author(s).
Conflict of interest statement
The authors have no competing interest to declare.
Similar articles
-
High seroprevalence of Immunoglobulin G (IgG) and IgM antibodies to SARS-CoV-2 in asymptomatic and symptomatic individuals amidst vaccination roll-out in western Kenya.PLoS One. 2022 Dec 22;17(12):e0272751. doi: 10.1371/journal.pone.0272751. eCollection 2022. PLoS One. 2022. PMID: 36548358 Free PMC article.
-
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1. Trials. 2021. PMID: 33849629 Free PMC article.
-
COVID-19 lateral flow IgG seropositivity and serum neutralising antibody responses after primary and booster vaccinations in Chile: a cross-sectional study.Lancet Microbe. 2023 Mar;4(3):e149-e158. doi: 10.1016/S2666-5247(22)00290-7. Epub 2023 Jan 27. Lancet Microbe. 2023. PMID: 36716754 Free PMC article.
-
Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.Front Public Health. 2022 Oct 6;10:967447. doi: 10.3389/fpubh.2022.967447. eCollection 2022. Front Public Health. 2022. PMID: 36276377 Free PMC article.
-
Seroprevalence of SARS-CoV-2 IgG antibodies in the staff of the Slovak Academy of Sciences in response to COVID-19 and/or vaccination: situation in August 2021.Acta Virol. 2021;65(4):420-432. doi: 10.4149/av_2021_407. Acta Virol. 2021. PMID: 34796716
Cited by
-
Population-based cross-sectional seroprevalence study of SARS-CoV-2 infection in urban residential areas in Ghana.BMJ Public Health. 2025 Jun 23;3(1):e001994. doi: 10.1136/bmjph-2024-001994. eCollection 2025. BMJ Public Health. 2025. PMID: 40557286 Free PMC article.
References
-
- World Health Organization . 2023. Coronavirus disease (COVID-19) pandemic.https://www.who.int/emergencies/diseases/novel-coronavirus-2019 [accessed 30 September 2023] - PubMed
-
- Ghana Health Service . 2023. Ghana's outbreak response management updates Accra: Ghana Health Service.https://www.ghs.gov.gh/covid19/ [accessed 30 September 2023]
LinkOut - more resources
Full Text Sources
Miscellaneous